Bioassay of cholecystokinin-pancreozymin in duodenal mucosa

Yolk vitronectin. Purification and differences from its blood homologue in molecular size, heparin binding, collagen binding, and bound carbohydrate.

The Journal of biological chemistry·1992

Effects of social isolation on pentobarbital activity in mice: relationship to racemate levels and enantiomer levels in brain.

The Journal of pharmacology and experimental therapeutics·1992

Scanning electron microscopy of intracellular organelles in the young odontoblasts of rats.

Scanning microscopy·1992

Protection by chlorpromazine against lethality and renal toxicity of cisplatin in mice.

Experientia·1992

Granulocyte-colony stimulating factor stimulates immunoreactive endothelin-1 release from cultured bovine endothelial cells.

European journal of pharmacology·1992

Purification and characterization of a diptericin homologue from Sarcophaga peregrina (flesh fly).

The Biochemical journal·1992

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Lancet (London, England)·2026

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

Lancet (London, England)·2026

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Lancet (London, England)·2026

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

Lancet (London, England)·2026

Survey of the human proteostasis network: the autophagy-lysosome pathway.

Autophagy·2026

Preparation of Phosphoinositide-Containing Supported Lipid Bilayers and Quantitative Assessment of Protein Recruitment to Membrane Surfaces.

Bio-protocol·2026

Survey of the human proteostasis network: translation, protein folding, and organelle-specific systems.

Autophagy·2026

SphK1/S1P signaling network: From molecular mechanism to therapeutic targeting.

Life sciences·2026

Targeting of Protein Persulfidation in Aging and Age-Related Disorders.

Pharmaceutics·2026

Systematic Identification of Candidate Substrates of the UCH Family of Deubiquitinases.

International journal of molecular sciences·2026

Related Experiment Videos

Bioassay of cholecystokinin-pancreozymin in duodenal mucosa

Related Concept Videos

Yolk vitronectin. Purification and differences from its blood homologue in molecular size, heparin binding, collagen binding, and bound carbohydrate.

Effects of social isolation on pentobarbital activity in mice: relationship to racemate levels and enantiomer levels in brain.

Scanning electron microscopy of intracellular organelles in the young odontoblasts of rats.

Protection by chlorpromazine against lethality and renal toxicity of cisplatin in mice.

Granulocyte-colony stimulating factor stimulates immunoreactive endothelin-1 release from cultured bovine endothelial cells.

Purification and characterization of a diptericin homologue from Sarcophaga peregrina (flesh fly).

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

Survey of the human proteostasis network: the autophagy-lysosome pathway.

Preparation of Phosphoinositide-Containing Supported Lipid Bilayers and Quantitative Assessment of Protein Recruitment to Membrane Surfaces.

Survey of the human proteostasis network: translation, protein folding, and organelle-specific systems.

SphK1/S1P signaling network: From molecular mechanism to therapeutic targeting.

Targeting of Protein Persulfidation in Aging and Age-Related Disorders.

Systematic Identification of Candidate Substrates of the UCH Family of Deubiquitinases.

Related Experiment Videos

Bioassay of cholecystokinin-pancreozymin in duodenal mucosa

Related Concept Videos

Related Articles